MedTrace Logo

An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

NCT00699608 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2012-06-05

Study results available
· View outcomes & findings →

Summary

This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.

Conditions

  • Healthy Subjects
  • Sleep Initiation and Maintenance Disorders

Interventions

DRUG

GSK1755165; placebo; zopiclone

Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00699608 on ClinicalTrials.gov